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Abstract
Background: HIV-1 targets human cells expressing both the CD4 receptor, which binds the viral envelope
glycoprotein gp120, as well as either the CCR5 (R5) or CXCR4 (X4) co-receptors, which interact primarily with the
third hypervariable loop (V3 loop) of gp120. Determination of HIV-1 affinity for either the R5 or X4 co-receptor on
host cells facilitates the inclusion of co-receptor antagonists as a part of patient treatment strategies. A dataset of
1193 distinct gp120 V3 loop peptide sequences (989 R5-utilizing, 204 X4-capable) is utilized to train predictive
classifiers based on implementations of random forest, support vector machine, boosted decision tree, and neural
network machine learning algorithms. An in silico mutagenesis procedure employing multibody statistical
potentials, computational geometry, and threading of variant V3 sequences onto an experimental structure, is used
to generate a feature vector representation for each variant whose components measure environmental
perturbations at corresponding structural positions.
Results: Classifier performance is evaluated based on stratified 10-fold cross-validation, stratified dataset splits (2/3
training, 1/3 validation), and leave-one-out cross-validation. Best reported values of sensitivity (85%), specificity
(100%), and precision (98%) for predicting X4-capable HIV-1 virus, overall accuracy (97%), Matthew’s correlation
coefficient (89%), balanced error rate (0.08), and ROC area (0.97) all reach critical thresholds, suggesting that the
models outperform six other state-of-the-art methods and come closer to competing with phenotype assays.
Conclusions: The trained classifiers provide instantaneous and reliable predictions regarding HIV-1 co-receptor
usage, requiring only translated V3 loop genotypes as input. Furthermore, the novelty of these computational
mutagenesis based predictor attributes distinguishes the models as orthogonal and complementary to previous
methods that utilize sequence, structure, and/or evolutionary information. The classifiers are available online at
http://proteins.gmu.edu/automute.
Background
Host cells targeted for entry by HIV-1 express the cellu-
lar CD4 receptor as well as a secondary cellular chemo-
kine co-receptor, principally either CCR5 (R5) or
CXCR4 (X4), all of which interact with the HIV-1
envelope glycoprotein gp120. Natural ligands for these
receptors include IL-16 (CD4); RANTES, MIP-1a,a n d
MIP-1b (R5); and SDF-1a (X4) [1]. Prior to being recog-
nized that successful viral entry necessarily requires that
gp120 also binds a co-receptor subsequent to CD4
attachment, HIV-1 strains were typically classified as
nonsyncytium (NSI)- or syncytium (SI)-inducing based
solely on their ability to induce syncytia in cell cultures,
which correlates with viral preference for infecting
monocyte-derived macrophages (M-tropic) or T-lym-
phocytes (T-tropic), respectively [2,3]. M-tropic strains
of HIV-1 often use the R5 co-receptor while T-tropic
strains use X4; however, there also exist dual- or mixed-
tropic (DM or R5/X4) strains capable of using both co-
receptors [4].
The significance of viral categorization based on co-
receptor usage is underscored by the observation that
while a majority of newly infected patients harbor only
R5-utilizing HIV-1 strains, X4 variants appear in
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disease accompanied by an accelerated decline in CD4+
T-lymphocytes and progression towards an AIDS diag-
nosis [5]. Co-receptors R5 and X4 interact to a great
extent with the third hypervariable loop (V3 loop) of the
HIV-1 envelope glycoprotein gp120 [6], a peptide frag-
m e n td i s t a n tf r o mt h eg p 1 2 0c o r ea n dc o m p r i s e do f3 5
amino acids with a disulfide bridge formed by cysteine
residues at the N- and C-termini (Fig. 1). This interac-
tion suggests that accumulation of amino acid replace-
ments at multiple positions within the V3 loop is
responsible for the eventual switch in co-receptor affi-
nity; however, there are competing arguments as to
whether V3 loop structural changes drive co-receptor
selectivity, or if one predominant conformation exists
for both R5 and X4 variants and that sequence changes
alone account for the switch in co-receptor usage [7,8].
Evidence suggesting a dual contribution was provided
by a study in which knowledge-based potentials were
used to assess the fitness of variant V3 loop sequences
on candidate structures generated by Markov Chain
Monte Carlo techniques applied to NMR data [9].
Widespread clinical success through HIV-1 combina-
tion drug therapy, targeting essential proteins at distinct
stages of the viral life cycle, is tempered by the emer-
gence of patient viral strains that are resistant to one or
more of these medications. Hence the identification of
healthy individuals, homozygous for a nonfunctional R5
due to a 32-base pair deletion and highly resistant to
HIV-1 infection [10], motivated the search for viable co-
receptor antagonists to include among the current
arsenal of treatments. The US Food and Drug Adminis-
tration recently approved the R5 inhibitor maraviroc
[11] for use in treatment-experienced individuals in
combination with other medications, and a number of
additional co-receptor antagonists are in various stages
of development [12,13]. Evaluation of viral co-receptor
tropism in patients is essential prior to and during clini-
cal administration of such antagonists so that only the
appropriate co-receptor is targeted, and in vitro experi-
mental assays are available; however, these phenotype
tests are costly and time-consuming, and their results
are not standardized [14]. Given these drawbacks, accu-
rate in silico models for predicting co-receptor tropism
Figure 1 HIV-1 gp120 V3 loop structure visualization, Delaunay tessellation, and variant representation. (a) Ribbon diagram and (b) Ca
trace of the V3 loop peptide structure (PDB ID: 1ce4, NMR model 1). (c) Delaunay tessellation of the V3 loop superimposed over the trace. (d)
3D-1D potential profiles for both the native R5-tropic V3 loop sequence corresponding to PDB structure file 1ce4, as well as an R5-tropic variant
V3 loop sequence defined by the five substitutions N5G, H13R, R18Q, T22A, and I26V threaded onto the native structure tessellation. The variant
residual profile is defined as the difference between the variant and native 3D-1D potential profiles and measures environmental perturbations
at all 35 V3 loop positions due to the substitutions.
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Page 2 of 11have generated considerable interest. The vast majority
of these methods rely on patient HIV-1 gp120 V3 loop
sequences easily obtained through relatively rapid and
inexpensive genotype tests, which are predicted to be
either strictly R5-tropic or X4-capable (i.e., X4 and R5/
X4 combined), since there are relatively far fewer
sequences that strictly use X4. For the sake of notational
simplicity, the DM acronym is modified in the remain-
der of this manuscript to refer to X4-capable virus,
yielding two co-receptor usage categories: R5 and DM.
The 11/25 charge rule refers to the earliest and sim-
plest predictive method reported [15], identifying HIV-1
with an SI phenotype based on the presence of posi-
tively charged residues at V3 loop positions 11 and/or
25 with good specificity though relatively poor sensitiv-
ity with respect to DM strains, the majority of which
induce syncytia [16,17]. A second approach utilized a
sequence based multiple linear regression and identified
four positive predictors of HIV-1 co-receptor tropism:
the number of positively (K/R) and negatively (D/E)
charged V3 sequence residues, the V3 net charge (K/R -
D/E), and the presence of I at gp120 position 292 out-
side of the V3 loop (V3 loop begins at C296) [18]. Next,
predictions of HIV-1 phenotype and co-receptor usage
have been obtained through position-specific scoring
matrix (PSSM) techniques [6,19,20]. Finally, several
models have been developed recently based on a variety
of supervised classification machine learning algorithms
utilizing V3 sequence and/or structure descriptors.
These algorithms have included neural network (NN)
[17,20], decision tree (DT) [20-22], support vector
machine (SVM) [20-23], and random forest (RF) [22,24].
The addition of structural attributes to the sequence
features of V3 loop variants was shown to significantly
improve classifier prediction performance [23].
In this article, we describe a computational mutagen-
esis methodology for characterizing HIV-1 gp120 V3
loop variants that involves threading of sequence (trans-
lated genotype) information onto a reference structural
template and relies on a four-body, knowledge-based
potential (Fig.1). For each V3 loop mutational pattern,
the approach yields both a scalar measure of overall
change in sequence-structure compatibility relative to
the native peptide, as well as a 35-dimensional vector
representing environmental perturbations at all V3 loop
residue positions caused by the amino acid replace-
ments. In particular, we demonstrate that sequence-
structure compatibility is more adversely affected among
DM-tropic strains relative to R5 variants in a non-
redundant dataset of 1193 V3 loop sequences with
known co-receptor tropism. Additionally, with each
sequence represented as a perturbation vector, the data-
set is used for training a variety of machine learning
algorithms. This novel approach utilizing both sequence
and structure, as well as combining machine learning
with an energy function-based mutagenesis for mutant
representation, was previously applied to develop accu-
rate models for predicting susceptibility to HIV-1 pro-
tease inhibitors [25]. The classifiers developed here are
shown to outperform other published models for V3
loop-based prediction of co-receptor usage, especially
with regard to the sensitivity of DM strain classification,
suggesting that signals inherent in these vectors are
more effective for discrimination between R5 and DM
viral strains. These models are also well suited to pro-
vide instantaneous predictions and require only V3 loop
sequences as input.
Methods
Dataset
A search of the HIV Sequence Database at Los Alamos
National Laboratory (http://www.hiv.lanl.gov/content/
sequence/HIV/mainpage.html, accessed in April 2009)
generated a total of 3986 HIV-1 gp120 V3 loop
sequences with annotated co-receptor phenotypes
obtained from treatment naïve and experienced patients
(3693 sequences associated with 738 distinct patients,
and 293 sequences with missing patient ID numbers),
spanning all HIV-1 subtypes and based on data obtained
from clinical trial studies in 39 countries over sampling
years 1983-2006. Upon translation and elimination of
duplicate sequences, the final dataset contained 1193
distinct 35-residue long V3 loop sequences, consisting
of 989 strictly R5-utilizing variants and 204 DM var-
iants. In order to be consistent with all other methods
to which we compare our results, and due to the paucity
of strictly X4 variants in the dataset, by convention the
DM category here more generally consists of X4-capable
sequences (i.e., both X4 and R5/X4 variants are
combined).
Computational mutagenesis methodology
Our in silico mutagenesis procedure relies on a four-
body, knowledge-based, statistical contact potential,
which provides an interaction empirical energy for each
of the 8855 permutation-free quadruplets of amino
acids that can be enumerated using a standard 20-letter
protein alphabet [26]. We generated the four-body
potential by analyzing a diverse dataset of 1417 high-
resolution (≤2.2Å) crystallographicp r o t e i ns t r u c t u r e s
with low sequence identity (<30%), culled from the Pro-
tein Data Bank (PDB) [27] using the PISCES server [28].
The Ca atomic coordinates of the constituent amino
acid residues were used to render each protein structure
as a discrete collection of points in 3-dimensional (3D)
space. Delaunay tessellation, a classical computational
geometry technique, was used to model each protein,
whereby Ca atoms served as vertices to generate a 3D
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gular, tetrahedral simplices [29]. Hundreds of simplices
are generated by the tessellation of an average sized pro-
tein, and the four vertices of each simplex objectively
identify a quadruplet of nearest neighbor amino acid
residues in the protein structure. For each of the 8855
amino acid quadruplets (i, j, k, l), a relative frequency of
occurrence fijkl was calculated based on the proportion
of simplices among the 1417 protein structure tessella-
tions whose vertices represent the four residues, and a
rate of quadruplet occurrence expected by chance pijkl
was obtained from a multinomial reference distribution
[26]. Energy of quadruplet interaction, modeled after the
inverse Boltzmann principle, was calculated as log(fijkl/
pijkl) [26,30].
Next, Delaunay tessellation was applied to a V3 loop
structure (PDB ID: 1ce4, model 1) containing an R5-tro-
pic sequence (JRCSF isolate), which is currently the only
available structure of the unliganded peptide [31]. Using
the four-body potential and tessellated V3 loop (Fig. 1)
[31,32], each of the constituent simplices was scored
according to the interaction energy of the amino acid
quadruplet represented by its vertices. A total of 130
tetrahedral simplices were generated by the V3 loop tes-
sellation, where all six edges for 105 simplices have
lengths less than 12Å, and the longest edge among the
remaining 25 simplices measures 20.93Å. The global
sum of the 130 simplex scores, referred to as the V3
loop total potential or topological score,p r o v i d e sa n
overall sequence-structure compatibility measure for the
native peptide [33-35]. For each V3 loop amino acid, an
individual residue potential or residue environment score
was calculated as the local sum of all simplices that
share the Ca atom of the amino acid as a vertex [34-37],
and an ordered representation of these scores by pri-
mary sequence position number as a 35-dimensional
vector forms a 3D-1D potential profile (Fig.1) [38].
For each particular V3 loop mutational pattern, the
new sequence of amino acid letters was threaded onto
the native tessellated V3 loop template structure by rela-
beling each of the 35 Ca vertices. While the tessellation
remains unaffected, simplices with one or more rela-
beled vertices are recast with altered scores due to new
residue quadruplet compositions, and recalculations
yield a topological score and 3D-1D potential profile for
the V3 loop variant. The difference between variant and
native V3 loop topological scores, referred to as the var-
iant residual score, measures relative change in overall
sequence-structure compatibility due to the residue sub-
stitutions [34-37]. Finally, the variant residual profile is
defined as the difference between the variant and native
V3 loop 3D-1D potential profiles and consists of com-
ponent values measuring environmental perturbations at
all V3 loop positions (Fig. 1) [35-37]. Conformational
changes in the protein structure are effectively taken
into account with this computational mutagenesis meth-
odology, both implicity, through the four-body potential
and variant residual scores and profiles, and explicitly,
due to the use of only coarse-grained Ca representations
of protein structures and the fact that Delaunay tessella-
tion is robust to small shifts in the Ca coordinates
[34-37].
Machine learning tools for prediction and evaluation of
performance
The dataset of 1193 HIV-1 gp120 V3 loop variants was
used to train and compare the performance of four
well-known supervised learning algorithms, random for-
est (RF), support vector machine (SVM), boosted deci-
sion tree (BDT), and neural network (NN), all available
as part of the Weka software package [39]. Residual pro-
files were utilized as input feature vectors for character-
izing V3 loop variants, and variant co-receptor tropism
(R5 or DM) represented the output attribute for the
classifiers. Non-default values of the adjustable para-
meters used in the implementation of these algorithms
include: one hundred bootstrapped datasets (i.e., one
hundred classification trees for majority vote) for RF;
radial basis function (RBF) kernel with g = 0.1, neither
normalization nor standardization of the training data,
and logistic models fit to the outputs for SVM; 50
boosted iterations using the Adaboost M1 method for
BDT; and no attribute normalization for NN.
Algorithm performance on the dataset was evaluated
by using stratified 10-fold cross-validation (10-fold CV),
leave-one-out cross-validation (LOOCV), and stratified
random split (66% of the dataset used for model training
and the remaining 34% used for prediction) testing pro-
cedures. Prediction results reported with 10-fold CV
and 66/34 split are based on averages over ten indepen-
dent iterations.
Assuming P (positive) refers to the DM class and N
(negative) refers to the R5 class, ACC = accuracy = (TP
+ TN)/(TP + FN + FP + TN) provides a simple measure
of the overall prediction success rate. Here, TP and TN
represent the number of correct DM and R5 predic-
tions, respectively, and FP and FN are misclassifications.
The balanced error (BER) and balanced accuracy (BAR)
rates, calculated as BER = 0.5 × [FN/(FN + TP) + FP/
(FP + TN)] and BAR = 1 - BER, Matthew’s correlation
coefficient (MCC), given by
MCC
TP TN-FP FN
(TP FN)(TP FP)(TN FN)(TN FP)
=
××
+++ +
,
and area (AUC) under the receiver operating charac-
teristic (ROC) curve provide additional measures of clas-
sifier performance that are especially useful for
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o ft h et r u ep o s i t i v er a t e( s e n s i t i v i t y )v e r s u st h ef a l s e
positive rate (1 - specificity), where sensitivity = Se(DM)
= TP/(TP + FN) and specificity = Sp(DM) = TN/(TN +
FP). An AUC value near 0.5 is indicative of random
guessing while a value of 1.0 denotes a perfect classifier.
Finally, positive predictive value or precision is defined
as PPV(DM) = TP/(TP + FP).
Results and Discussion
Variant V3 loop dataset sequence analysis
For each co-receptor usage class, variant HIV-1 gp120
V3 loop sequences were aligned and sequence logos
[40] were generated to visualize relative amino acid fre-
quencies at each position and to identify highly con-
served positions (Fig. 2). Similarities (e.g., highly
conserved cysteine residues at terminal positions) and
differences (e.g., amino acid relative frequencies at posi-
tions 11/25) are clearly evident between both logos.
Additionally, histograms were produced for each co-
receptor class based on the number of amino acid sub-
stitutions in the variant V3 loop sequences relative to
the native sequence of the tessellated structure (Fig. 3a).
The average number of V3 loop residue replacements
was calculated as 5.6 ± 2.4 for the R5 class and 8.8 ±
4.2 for the DM class, and a t-test revealed a statistically
significant difference between class mutation averages
(p < 0.0001). These data suggest that a greater accumu-
lation of mutations is associated with a switch in co-
receptor affinity, which may be due to either V3 loop
conformational changes or stochastic accumulation of
minor mutations prior to co-receptor switch substitu-
tions at sequence positions 11/25.
B a s e do na na n a l y s i so fv a r i a n tV 3l o o pc h a n g e si n
sequence-structure compatibility relative to the native
peptide (i.e., the variant residual scores), stark differ-
ences also exist between the R5 and DM co-receptor
classes. The mean residual score was calculated to be
0.32 for the 989 V3 loop variants comprising the R5
class and -0.60 for the 204 DM-tropic variants, and a t-
Figure 2 V3 loop sequence logos for the 989 R5 and 204 DM dataset variants. The size of the letters at each position is indicative of their
relative frequencies of occurrence among the sequences in the co-receptor class. The red arrows identify the top ten positions in the variant
residual profile vectors for predicting co-receptor phenotype, ranked by an SVM classifier and a 10-fold CV attribute selection mode.
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class mean residual scores (p < 0.0001). These results
strongly suggest that the continual accumulation of
mutations in the DM class is ultimately detrimental to
V3 loop sequence-structure compatibility.
Finally, with each V3 loop variant represented by its
respective 35-dimensional residual profile vector of
environmental perturbation scores, an unsupervised
clustering of the variants was performed using the
expectation-maximization (EM) algorithm available with
the Weka software package [39]. For each variant, the
EM algorithm calculates probabilities of membership in
each of the available clusters, and the algorithm uses a
cross-validation procedure to automatically determine
the number of clusters. A total of 17 clusters were gen-
erated, each labeled as either R5 or DM based on major-
ity class size (Fig. 3b). Cluster purity, defined as
Purity  max precision = () {} ∑
n
n
ij
j
j
i ,
where precision (i, j) refers to the relative frequency of
class i in cluster j, nj is the number of sequences in clus-
ter j,a n dn = 1193 is the dataset size, is 90.4%. The
clustering can be associated with a guiding tree that
reflects the distances between V3 loops in a sequence
space and likely corresponds to the evolutionary history
of the virus. Thus, given a training set of V3 sequences
Figure 3 Data analysis and clustering of V3 loop variant sequences. (a) Histograms for the sets of R5 and DM V3 loop variant sequences
based on the number of residue substitutions relative to the native sequence of PDB structure 1ce4. (b) Unsupervised EM clustering of the
variant V3 loop sequence dataset based on their residual profile representations yields a cluster purity measure of 90.4%.
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points, starting from early stages of infection, it would
be possible to build a model to correlate V3 sequence
position in a tree and likelihood of a switch in co-recep-
tor usage.
Predictive performance of variant V3 loop residual
profiles
Four supervised classification algorithms (RF, SVM,
BDT, and NN) were utilized for assessing predictive per-
formance of the environmental perturbation descriptors
encoded by the variant V3 loop residual profile vectors,
and results were reported based on application of 10-
fold CV, LOOCV, and 66/34 split testing procedures
(Table 1). The testing methods and algorithms all gener-
ated relatively consistent results with the exception of
slightly lower values based on NN. In order to highlight
the strength of signals embedded in the variant V3 loop
residual profiles for accurately discriminating between
R5-utilizing and DM (X4-capable) sequences, we com-
pared the LOOCV results of Table 1 using the original
dataset with those obtained using a control dataset gen-
erated by a randomly shuffling of the R5 and DM class
labels among the V3 loop variants so that the class sizes
are unaltered. Striking AUC reductions to levels near
0.5 were observed using the control dataset (Fig. 4a),
suggesting that models developed with the control are
not likely to perform better than random guessing, a
conclusion further supported by MCC and BER mea-
sures: RF (MCC = 0.01, BER = 0.49), SVM (MCC =
-0.02, BER = 0.51), BDT (MCC = -0.01, BER = 0.50),
and NN (MCC = -0.02, BER = 0.51). For a more sys-
tematic approach to assessing the statistical significance
of our results in Table 1, we generated 1,000 class label
permutations (random shuffles) and calculated 10-fold
CV performance in each case based on the SVM algo-
rithm. The distributions of MCC and BAR accuracy
measurements (Fig. 4b) are narrowly centered around
zero and 0.5, respectively (MCC = 0.00 ± 0.03, BAR =
0.50 ± 0.02), with no permutation accuracy approaching
those obtained using the original arrangement of the
class labels (Table 1: MCC = 0.81 ± 0.01, BAR = 1 -
BER = 0.90 ± 0.01), so that the p-value for predictive
power is less than 0.001. Results nearly identical to
these were also obtained using the RF (MCC = 0.00 ±
0.03, BAR = 0.50 ± 0.01), BDT (MCC = 0.00 ± 0.03,
BAR = 0.50 ± 0.01), and NN (MCC = 0.00 ± 0.03, BAR
= 0.50 ± 0.02) algorithms, whereby 10-fold CV was
applied to each of 1,000 new random class label shuffles
generated for each of the three methods, and these data
Table 1 Comparison of performance measures
Method ACC Se(DM) Sp(DM) PPV(DM) AUC MCC BER
RF (LOOCV) 0.96 0.82 0.99 0.95 0.97 0.86 0.09
RF (10-fold CV)
a 0.96 0.82 0.99 0.95 0.97 0.87 0.09
RF (66/34 split)
a 0.96 0.84 0.99 0.94 0.97 0.87 0.08
SVM (LOOCV) 0.95 0.84 0.97 0.87 0.95 0.82 0.09
SVM (10-fold CV)
a 0.95 0.83 0.97 0.86 0.95 0.81 0.10
SVM (66/34 split)
a 0.95 0.85 0.97 0.84 0.96 0.81 0.09
BDT (LOOCV) 0.96 0.82 0.99 0.97 0.97 0.87 0.09
BDT (10-fold CV)
a 0.96 0.80 0.99 0.96 0.97 0.85 0.10
BDT (66/34 split)
a 0.97 0.83 1.00 0.98 0.97 0.89 0.08
NN (LOOCV) 0.95 0.80 0.98 0.87 0.95 0.80 0.11
NN (10-fold CV)
a 0.95 0.80 0.98 0.86 0.95 0.80 0.11
NN (66/34 split)
a 0.94 0.82 0.97 0.83 0.95 0.79 0.11
Sander et al.
(SVM, 10-fold CV)
a 0.92 0.80 0.95 0.81 0.93 ——— ———
Prosperi et al.
(RF, 10-fold CV)
a 0.88 0.63 ——— ——— 0.88 ——— ———
Prosperi et al.
(SVM, 10-fold CV)
a 0.90 0.69 ——— ——— 0.91 ——— ———
Sing et al.
(SVM, 10-fold CV)
a ——— 0.76 0.93 ——— ——— ——— ———
Xu et al.
(RF, 56/42 split)
b 0.95 0.85 0.98 0.99 ——— 0.87 ———
Pillai et al.
(SVM, 10-fold CV)
c 0.91 0.76 0.98 0.95 ——— ——— ———
Resch et al.
(NN, 50/50 split)
c ——— 0.75 0.94 0.69 ——— ——— ———
aaverage over 10 iterations;
bsingle split - use of duplicates inflates performance;
caverage over 100 iterations
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each of the algorithms based on the original class label
arrangement as provided in Table 1.
Our sequence-structure approach, combining machine
learning with an energy-based computational mutagen-
esis for generating variant V3 loop sequence feature vec-
tors, outperformed the structure-based approach of
Sander et al. [23] and the sequence-based approaches of
Prosperi et al. [22], Sing et al. [20], Xu et al. [24], Pillai
et al. [21], and Resch et al. [17] (Table 1). These studies
all obtained datasets from the Los Alamos HIV
Sequence Database in an approach similar to the one
outlined in this manuscript. Sander et al. and Sing et al.
utilized the SVM algorithm along with a 10-fold CV
testing procedure, Prosperi et al. used the RF and SVM
algorithms with 10-fold CV, and the results of all three
groups reflect an average over ten iterations. Xu et al.
applied the RF algorithm with only a single 56/44
Figure 4 Statistical significance of classifier performance. (a) LOOCV ROC curves for all four models based on the original dataset as well as
a control obtained via a single random permutation of the R5/DM class labels among the V3 loop variants in the dataset. (b) Distribution of 10-
fold CV SVM prediction performance (BAR - balanced accuracy rate and MCC - Matthew’s correlation coefficient) over 1,000 permutations
(random shuffles) of the class labels, compared with similar measurements obtained using the class label arrangement of the original dataset.
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contained an abundance of duplicates that were not
removed prior to the split. While duplicates within the
test set were subsequently removed prior to evaluating
performance, duplicates between the training and test
sets were not addressed, which would artificially inflate
the reported performance. Pillai et al. utilized the SVM
algorithm and averaged the results over 100 iterations of
10-fold CV. Lastly, Resch et al. implemented an NN
algorithm and reported results based on 100 iterations
of 50/50 random splits.
The practical value of these models is measured by
their ability to reliably predict co-receptor usage classes
for V3 sequences not appearing in the training dataset,
therefore constituting an independent test set. Yet
obtaining and annotating additional testing samples in a
timely way is often not feasible. Alternatively, stratified
random split of an annotated dataset of distinct V3
sequences into one subset for training and another for
testing, such as those two-subset splits whose results are
reported in Table 1, accurately reflect the performance
expected by trained models on independent test sets. In
a recent study, Low et al. [16] evaluated six algorithms
with a test set of 920 V3 sequences whose co-receptor
usage annotations are not available in the public data-
bases. They reported Se(DM) values in the 0.24 - 0.50
range, discounting utility of the models. However, these
difficulties were likely encountered because over 50% of
test sequences have ambiguous amino acids. Low et al.
[16] subsequently proposed that reliable models should
achieve Se(DM) ≥ 0.85 on test sets, a level equivalent to
the concordance of co-receptor phenotype assays.
Though our SVM model does achieve this threshold,
the overall methodology suffers from an important
drawback that limits its applicability: all V3 sequences,
which may be either from majority or minority HIV-1
viral species, must consist of exactly 35 amino acids (i.e.,
no indels) that are selected from the standard 20-letter
protein alphabet, without ambiguities.
The PDB structure 1ce4 was determined using NMR
techniques and consists of 20 models, with model 1
representing the best conformer (lowest target energy
function). In order to assess the impact of the confor-
mation on the results, we repeated our analysis by gen-
erating an analogous training set based on the use of
model 20 and obtaining 10-fold CV performance values.
The vast majority of the values obtained using both con-
formations were within two percentage points of each
other, suggesting consistency across all conformers
(model numbering corresponds to target function rank-
ings). In particular, Se(DM) measures are identical using
both models in the case of RF as well as SVM, while for
BDT and NN they differ by one (0.81 vs. 0.80) and two
(0.82 vs. 0.80) percentage points, respectively.
Additionally, we evaluated contribution of structure
information to performance by representing V3 loop
sequences in the training set simply based on 4-mer
consecutive string clusters. A sliding window of size
four over the 35-residue V3 sequence generates 32 such
overlapping 4-mer clusters, each of which is represented
as a 20-dimensional vector of amino acid counts, and
they are appended to form a 640-dimensional vector for
each V3 sequence. This sequence-based training set
yielded Se(DM) values in the 0.70 - 0.73 range (com-
pared to 0.80 - 0.85 with our structure-based approach),
and a paired t-test using this data confirmed a statisti-
cally significant improvement in performance due to the
structural component (p < 0.001).
Next, learning curves were plotted in order to assess
the influence of dataset size on performance, using the
RF algorithm as an example (Fig. 5). We generated ten
stratified random samples each consisting of 200 variant
V3 sequences, where each sample was selected from
among the full dataset of 1193 sequences, and mean 10-
fold CV performance measures were calculated. Subse-
quent iterations involved incrementing by 200 mutants
the sizes of the ten sampled datasets. The curves clearly
reflect that the availability of larger datasets for training
leads to significant improvements in RF algorithm per-
formance. With the current dataset size, the learning
curves have not reached plateaus, which suggests that
additional sequences will further improve performance.
This increase in performance may be due to overcoming
implicit confounding effects of clade and phylogenetic
relatedness that may currently exist in the dataset.
Finally, we attempted to rank the relative importance
of the variant V3 loop feature vector components
Figure 5 Learning curves. Learning curves based on the 10-fold
CV performance of the RF algorithm on stratified subsets of
increasing size randomly selected from the original dataset. Ten
subsets are generated at each size interval, and the average of their
performance measures is reported. The availability of additional
training data clearly improves performance
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Page 9 of 11(environmental perturbations at each of the 35 positions
in the residual profiles) based on their respective contri-
butions to prediction performance. An SVM classifier
was used to rank the attributes by the square of the
weights assigned by the SVM, based on the results of a
10-fold CV attribute selection mode. The top ten posi-
tions are highlighted by red arrows in Fig. 2 and include
positions 11 and 25.
Conclusions
Variant V3 loop feature vectors generated by the com-
bined sequence-structure in silico mutagenesis metho-
dology described in this manuscript have been shown to
encode signals that robustly discriminate between the
R5 and DM classes, yielding universally reliable predic-
tive models based on a variety of supervised classifica-
tion machine learning algorithms. Simplicity is a key
ingredient to our approach that takes only variant V3
sequence as input and provides instantaneous predic-
tions, whereas the technique of Sander et al. [23]
involves the modeling of mutant structures, which is
expensive, cumbersome, and cannot be completely auto-
mated. On the other hand, our methodology is
restricted to only 35-residue V3 sequences and cannot
accommodate indels or non-standard amino acids,
which the Sander et al. method is capable of processing.
Our models display a modest yet vital improvement in
Se(DM) values relative to other published methods. For
the SVM classifier in particular, Se(DM) reaches the cri-
tical reliability threshold of 0.85 ascertained by Low
et al. [16]; hence, within the limitations imposed by our
approach, this SVM model is capable of correctly deter-
mining HIV-1 co-receptor tropism in a timely, inexpen-
sive manner relative to phenotype assays.
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